Does TRICARE Cover Ozempic in 2026? Military Coverage for GLP-1

No GLP-1 had a more turbulent two years of insurance news than Zepbound: excluded by America's biggest pharmacy benefit manager, approved for sleep apnea, added to a historic Medicare pilot, all while head-to-head trials confirmed it as the most effective weight-loss injection on the market. Where coverage stands now depends entirely on whose card is in your wallet.

Insurance coverage for Zepbound in 2026 is genuinely split. CVS Caremark and Aetna exclude it from standard formularies (Wegovy preferred), Cigna and UnitedHealthcare kept it covered with prior authorization, Blue Cross varies by state with Michigan and Massachusetts restricting, Medicare covers it for sleep apnea now and adds weight-loss coverage July 1, 2026 through the GLP-1 Bridge pilot, about 13 state Medicaid programs cover weight-loss GLP-1s, and TRICARE covers it with BMI-based prior authorization. Where covered, criteria center on a BMI of 30 or higher, or 27 or higher with a weight-related condition.

This hub maps every major payer, then routes you to the deep guide for your specific card.

Zepbound Coverage by Carrier: The 2026 Map

Deep guides per carrier: Aetna, Cigna, UnitedHealthcare, Blue Cross, BCBS, Blue Cross Blue Shield, Medicare, Kaiser, TRICARE, and Humana.

The Three Events That Shaped 2026 Coverage

First, the Caremark exclusion. On July 1, 2025, CVS Caremark removed Zepbound from its standard formularies in a pricing deal with Novo Nordisk, transferring existing authorizations to Wegovy, a move Healthcare Dive reported reshaped roughly a third of the commercial market. The exclusion held through 2026 formulary updates.

Second, the sleep apnea approval. The FDA's December 2024 decision made Zepbound the first drug for moderate-to-severe obstructive sleep apnea in adults with obesity, creating a disease-treatment pathway that works even on plans excluding weight-loss drugs, including Medicare.

Third, the federal pricing deal. The November 2025 agreement set a $245 monthly price for Medicare and Medicaid and funded the Medicare GLP-1 Bridge pilot covering the Zepbound KwikPen for weight management from July 1, 2026 with $50 copay caps, per NPR.

Universal Criteria Where Coverage Exists

Whatever the carrier, the clinical bar tracks the FDA label: a BMI of 30 or higher, or 27 or higher with at least one weight-related condition such as hypertension, prediabetes, dyslipidemia, or sleep apnea. Most plans add documented lifestyle-program participation (3 to 6 months), many apply Wegovy-first step therapy, and renewals almost universally require at least 5 percent weight loss from baseline.

Build the file before the first submission: baseline BMI and weight history, comorbidity documentation, program notes, prior GLP-1 trials, and the sleep study if OSA is in play. Complete files clear in 24 to 72 hours; thin ones become the denials that clog appeal queues for months.

What Zepbound Costs in Every Scenario

Covered with approval, commercial copays run $30 to $200 monthly depending on plan design, with Eli Lilly's commercial savings card bringing eligible insured patients down further, sometimes to $25. High-deductible members pay negotiated rates of roughly $750 to $950 until deductibles are met. Medicare's pathways carry the $50 monthly cap on the $245 negotiated price.

Without coverage, the self-pay ladder is the market's safety net: LillyDirect single-dose vials at $349 (2.5 mg starter) to $499 (higher doses) monthly, KwikPens around $399 to $449, and the federal TrumpRx channel listing tirzepatide near $346 as it phases in through 2026. List price sits at about $1,086 and should never be paid at a counter.

When You're Denied: The Escalation Playbook

Read the denial letter, because the reason picks the play. Category exclusion (employer never bought the benefit): take it to HR, where the new $200-copay structures make adding coverage cheaper than benefits teams assume, or use self-pay while documenting. Formulary exclusion (Caremark plans): file a medical-necessity exception anchored on a failed Wegovy trial or OSA diagnosis; plans must answer within 72 hours. Clinical denial: fix the named documentation gap and resubmit.

Formal appeals stack behind all of it: internal review decided within 30 days (72 hours expedited), then federally guaranteed external review by an independent physician. Appeals with complete BMI documentation and failed-alternative histories succeed at rates that surprise people, because the criteria are objective and the clinical literature on tirzepatide is strong.